Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, is pleased to announce that it has been awarded ‘Company of the Year’ at the 2016 Bionow Annual Awards.
Carl Sterritt, Chief Executive Officer of Shield Therapeutics, said: “We are honoured to have won the Bionow Company of the Year Award. This is recognition of the progress Shield Therapeutics has made over the past 12 months, which has been an incredible period for the Company, initiated by the completion of our IPO on AIM in February when we successfully raised £32.5m and receipt of a European Marketing Authorisation for Feraccru® – a treatment indicated in adults for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease – which has allowed us to begin commercialisation in Europe, meaning the Company is now one of a select group of revenue producing specialty pharma companies in the UK. This award not only recognises these achievements, but is a significant recognition for the staff at Shield Therapeutics whose tireless work and professionalism has delivered this success. I would like to thank them and we look forward to continuing to build on this success into 2017 and beyond.”
With around 1000 life science and healthcare companies and a combined turnover of £10.9bn, the North of England has the breadth of business, depth of expertise and investment in specialist infrastructure that rivals anything that any other UK region can offer and the Bionow Awards recognise this success and achievement.Back to news